iCo Therapeutics Inc.

Recent News

  • iCo Therapeutics Inc. Proposes to Re-Price Warrants

    Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), announces that they are submitting an application to the TSX Venture Exchange to amend the exercise price of 66,200,000 previously granted common share purchase warrants (the "Warrants") issued pursuant to a private placement of 25,000,000 units that was completed over several tranches from January 31, 2019 to March 4, 2019 (the "Spring 2019 Private Placement") and pursuant to a private...

    2021-01-11 8:21 PM ET
  • iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical

    Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), iCo Therapeutics, Inc. ("iCo") and Skymount Medical, Inc. ("Skymount") announced today that they have entered into a non-binding Memorandum of Understanding to develop iCo-019, iCo's oral Amphotericin B formulation. Skymount will initially commit up to $US 550,000 for pre-clinical work targeting the use of iCo-019 as a therapeutic product for infections relating to COVID-19."I am delighted that Skymount has recognized...

    2020-12-31 8:00 AM ET
  • iCo Therapeutics Announces Third Quarter 2020 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "We have aggressively continued to contain our operating expenses quarter over quarter and year over year. This has allowed us to increase the visibility of...

    2020-11-24 5:00 PM ET
  • iCo Therapeutics Announces Option Grants

    Vancouver, British Columbia--(Newsfile Corp. - October 26, 2020) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today granted 1,535,000 stock options to directors, officers and a contractor.The stock options are exercisable at the price of $0.05 and will expire on October 25, 2025. The stock options shall vest as follows: 1/5 on today's date (the "Effective Date") and then 1/5 every six months until all options are vested. The closing price of the Company's shares on...

    2020-10-26 6:37 PM ET
  • iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 - November 3rd, 2020

    Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that two poster presentations regarding iCo's Oral Amphotericin B technology (iCo-019) will be highlighted at the AAPS 2020 PharmSci 360 Virtual Meeting October 26 - November 5, 2020.AAPS is the preeminent global scientific organization of more than 10,000 actively participating pharmaceutical scientists from industry, academia, government, and other related...

    2020-10-21 7:00 AM ET
  • iCo Therapeutics Announces Second Quarter 2020 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "Our Q2 results show a marked quarter over quarter decline in our operating expenses compared to Q1, having substantially completed our Australian Phase 1b trial...

    2020-08-31 3:58 PM ET
  • iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal

    Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today the publication of results of their Oral Amphotericin B (iCo 019) Phase 1a Study in one of the leading infectious diseases journals, Antimicrobial Agents and Chemotherapy entitled "Phase I Clinical Study to evaluate the safety, tolerability, and pharmacokinetics of a novel oral amphotericin B formulation (ICO-019) in healthy human subjects"...

    2020-07-30 7:57 PM ET
  • iCo Therapeutics Announces First Quarter 2020 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended March 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "We were pleased with the positive outcome from our Phase 1b study of our oral amphotericin B asset during the quarter and that we were...

    2020-07-13 6:36 PM ET